Oligometastatic prostate cancer (omPCa) is a novel intermediate disease state characterized by a limited volume of metastatic cells and specific locations. Accurate staging is paramount to unmask oligometastatic disease, as provided by prostate-specific membrane antigen-positron emission tomography. Driven by the results of prospective trials employing conventional and/or modern staging modalities, the treatment landscape of omPCa has rapidly evolved over the last years. Several treatment-related questions comprising the concept of precision strikes are under development. For example, beyond systemic therapy, cohort studies have found that cytoreductive radical prostatectomy (CRP) can confer a survival benefit in select patients with omPCa. More importantly, CRP has been consistently shown to improve long-term local symptoms when the tumor progresses across disease states due to resistance to systemic therapies. Metastasis-directed treatments have also emerged as a promising treatment option due to the visibility of oligometastatic disease and new technologies as well as treatment strategies to target the novel PCa colonies. Whether metastases are present at primary cancer diagnosis or detected upon biochemical recurrence after treatment with curative intent, targeted yet decisive elimination of disseminated tumor cell hotspots is thought to improve survival outcomes. One such strategy is salvage lymph node dissection in oligorecurrent PCa which can alter the natural history of progressive PCa. In this review, we will highlight how refinements in modern staging modalities change the classification and treatment of (oligo-)metastatic PCa. Further, we will also discuss the current role and future directions of precision surgery in omPCa.

• Klíčová slova
• PSMA-PET, cytoreductive radical prostatectomy, metastasis-directed therapy, oligometastasis, oligometastatic, prostate neoplasms,
• MeSH
• lidé MeSH
• nádory prostaty * chirurgie   MeSH
• PET/CT metody   MeSH
• prospektivní studie MeSH
• prostata MeSH
• prostatektomie MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH

Natural killer (NK) cells represent a subset of CD3- CD7+ CD56+/dim lymphocytes with cytotoxic and suppressor activity against virus-infected cells and cancer cells. The overall potential of NK cells has brought them to the spotlight of targeted immunotherapy in solid and hematological malignancies, including multiple myeloma (MM). Nonetheless, NK cells are subjected to a variety of cancer defense mechanisms, leading to impaired maturation, chemotaxis, target recognition, and killing. This review aims to summarize the available and most current knowledge about cancer-related impairment of NK cell function occurring in MM.

• Klíčová slova
• NK cells, activating receptors, immunotherapy, inhibitory receptors, microenvironment, multiple myeloma, niche,
• MeSH
• biologické markery MeSH
• buňky NK imunologie   metabolismus   MeSH
• cílená molekulární terapie MeSH
• cytotoxicita imunologická MeSH
• imunita MeSH
• imunomodulace účinky léků   MeSH
• lidé MeSH
• management nemoci MeSH
• mnohočetný myelom diagnóza   etiologie   metabolismus   terapie   MeSH
• náchylnost k nemoci MeSH
• nádorové mikroprostředí účinky léků   imunologie   MeSH
• prognóza MeSH
• receptory buněk NK genetika   metabolismus   MeSH
• T-lymfocyty - podskupiny imunologie   metabolismus   MeSH
• výsledek terapie MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• přehledy MeSH
• Názvy látek
• biologické markery MeSH
• receptory buněk NK MeSH